Showing results (41-50 of 81) with videos related to
Sort By:
Pageof 9
Clinical Lung Cancer|June 1, 2019
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine PracticePhilippe Jamme, Clotilde Descarpentries, Radj Gervais, et al.BMC Cancer|December 21, 2019
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancerManon Kissel, Isabelle Martel-Lafay, Justine Lequesne, et al.Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 16, 2018
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic CharacteristicsLéonie Ferrer, Matteo Giaj Levra, Marie Brevet, et al.Lung Cancer (Amsterdam, Netherlands)|June 18, 2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancerRadj Gervais, John D Hainsworth, Normand Blais, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trialJean-Yves Douillard, Frances A Shepherd, Vera Hirsh, et al.Therapeutic Advances in Medical Oncology|May 5, 2021
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial <i>versus</i> "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasisIsabelle Monnet, Alain Vergnenègre, Gilles Robinet, et al.The European Respiratory Journal|September 19, 2015
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504Jacques Cadranel, Radj Gervais, Patrick Merle, et al.Frontiers in Oncology|December 15, 2025
Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancerJean Cabon, Delphine Lerouge, Sebastien Thureau, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2019
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesRonan Flippot, Pamela Biondani, Edouard Auclin, et al.Pageof 9